TITLE

Impact of new Therapies on Nursing Care

PUB. DATE
March 2002
SOURCE
Bone Marrow Transplantation;3/2/2002 Supplement, Vol. 29 Issue 5, pS255
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Bone Marrow Transplantation (2001) 29, Suppl. 2, S255–S256. DOI: 10.1038/sj/bmt/1703498
ACCESSION #
8890370

 

Related Articles

  • Nurses Group Poster Session.  // Bone Marrow Transplantation;Apr2013 Supplement, Vol. 48, pS476 

    The article presents abstracts on nursing and medical topics including "Patient therapeutic education programme after allogeneic stem cell transplantation," by N. Lancelle and colleagues, "The KFSH&RC (Saudia Arabia) Stem Cell Donor Registry experience," by R. Belkhedim and "Palliative care in...

  • Therapeutic advancements in multiple myeloma. Gozzetti, Alessandro; Candi, Veronica; Papini, Giulia; Bocchia, Monica // Frontiers in Oncology;Sep2014, Vol. 4, p1 

    Multiplemyeloma survival has significantly improved in the latest years due to a broad spectrum of novel agents available for treatment. The introduction of thalidomide, bortezomib, and lenalidomide together with autologous stem-cell transplantation has considerably increased complete remission...

  • New treatments in multiple myeloma: beyond optimal treatment. Harousseau, J.-L. // Annals of Oncology;Jun2008 Supplement 5, Vol. 19, pv68 

    The article looks at novel treatments in multiple myeloma which were made possible by the introduction of thalidomide, its analogue lenalidomide, and bortezomib. It discusses the side effects of combining the three novel agents with several drugs. The article also discusses findings on...

  • Initial therapy in multiple myeloma: investigating the new treatment paradigm. Kettle, Jacob K.; Finkbiner, Karen L.; Klenke, Susan E.; Baker, Ronald D.; Henry, Dave W.; Williams, Casey B. // Journal of Oncology Pharmacy Practice;Sep2009, Vol. 15 Issue 3, p131 

    The development of three novel chemotherapeutic agents - thalidomide, lenalidomide, and bortezomib - has resulted in a fundamental shift in the management of multiple myeloma. Despite this tremendous advancement, the selection of initial treatment must still be made with a degree of uncertainty...

  • Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. Hus, Marek; Grzasko, Norbert; Szostek, Marta; Pluta, Andrzej; Helbig, Grzegorz; Woszczyk, Dariusz; Adamczyk-Cioch, Maria; Jawniak, Dariusz; Legiec, Wojciech; Morawska, Marta; Kozinska, Justyna; Waciński, Piotr; Dmoszynska, Anna // Annals of Hematology;Oct2011, Vol. 90 Issue 10, p1161 

    The treatment of patients with multiple myeloma usually includes many drugs including thalidomide, lenalidomide and bortezomib. Lovastatin and other inhibitors of HMG-CoA reductase demonstrated to exhibit antineoplasmatic and proapoptotic properties in numerous in vitro studies involving myeloma...

  • First-Line Treatment of Multiple Myeloma in Elderly Patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Multiple Myeloma Working Party Perspective. Musto, Pellegrino; D'Auria, Fiorella; Pietrantuono, Giuseppe; Baldini, Luca; Bringhen, Sara; Caravita, Tommaso; Di Raimondo, Francesco; Morabito, Fortunato; Offidani, Massimo; Petrucci, Maria Teresa; Tosi, Patrizia; Gay, Francesca; Cavo, Michele; Boccadoro, Mario; Palumbo, Antonio // Current Drug Targets;Oct2009, Vol. 10 Issue 10, p906 

    No abstract available.

  • Non-myeloablative allogeneic transplantation (‘microallograft’) for refractory myeloma after two preceding autografts: feasibility and efficacy in a patient with active aspergillosis. Singhal, S; Safdar, A; Chiang, K Y; Godder, K; van Rhee, F; Garner, F; Foster, B; Dubovsky, D; Henslee-Downey, P J; Mehta, J // Bone Marrow Transplantation;12/1/2000, Vol. 26 Issue 11, p1231 

    A 59-year-old man with a 4-year history of light chain myeloma relapsing after two preceding autografts and salvage therapy with thalidomide underwent a peripheral blood stem cell (PBSC) transplant from his HLA-identical sister after conditioning with 100 mg/m2melphalan. Graft-versus-host...

  • Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. Kuwabara, S.; Misawa, S.; Kanai, K.; Sawai, S.; Hattori, I.; Nishimura, M.; Nakaseko, C. // Journal of Neurology, Neurosurgery & Psychiatry;Nov2008, Vol. 79 Issue 11, p1255 

    Background: Polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes (POEMS) syndrome is a rare multi-system disorder associated with plasma-cell dyscrasia. Several case series and reports have suggested that high-dose chemotherapy with autologous peripheral blood stem-cell...

  • Treatment options for myeloma. Meenaghan, Teresa; Kelly, Mary; Dowling, Maura // British Journal of Nursing;10/9/2013, Vol. 22 Issue 18, p1084 

    The article opines nurses in their roles of care giver and patient educator need to know about the adverse effects of myeloma treatment and also gives information about myeloma treatment options. The effectiveness and side effects of the immunomodulatory drugs thalidomide, lenalidomide, and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics